Phathom Pharmaceuticals Concludes Patient Enrollment for Phase 2 Trial

Phathom Pharmaceuticals, Inc. has announced the successful completion of patient enrollment for its ongoing Phase 2 study. This milestone, disclosed in an 8-K filing, marks a significant step forward in the clinical development process for the company's therapeutic candidates. The completion of enrollment allows the study to progress towards data collection and analysis.